Homology Modeling, Molecular Docking, Molecular Dynamic Simulation, and Drug-Likeness of the Modified Alpha-Mangostin against the β-Tubulin Protein of IAcanthamoeba Keratitis/I

Acanthamoeba species are capable of causing amoebic keratitis (AK). As a monotherapy, alpha-mangostin is effective for the treatment of AK; however, its bioavailability is quite poor. Moreover, the efficacy of therapy is contingent on the parasite and virulent strains. To improve readiness against A...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2022-09, Vol.27 (19)
Main Authors: Ongtanasup, Tassanee, Mazumder, Anisha, Dwivedi, Anupma, Eawsakul, Komgrit
Format: Article
Language:English
Subjects:
Analysis
Drug therapy
Hydrogen
Keratitis
Molecular dynamics
Tubulins
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 19
container_start_page
container_title Molecules (Basel, Switzerland)
container_volume 27
creator Ongtanasup, Tassanee
Mazumder, Anisha
Dwivedi, Anupma
Eawsakul, Komgrit
description Acanthamoeba species are capable of causing amoebic keratitis (AK). As a monotherapy, alpha-mangostin is effective for the treatment of AK; however, its bioavailability is quite poor. Moreover, the efficacy of therapy is contingent on the parasite and virulent strains. To improve readiness against AK, it is necessary to find other derivatives with accurate target identification. Beta-tubulin (BT) has been used as a target for anti-Acanthamoeba (A. keratitis). In this work, therefore, a model of the BT protein of A. keratitis was constructed by homology modeling utilizing the amino acid sequence from NCBI (GenBank: JQ417907.1). Ramachandran Plot was responsible for validating the protein PDB. The verified BT PDB was used for docking with the specified ligand. Based on an improved docking score compared to alpha-mangostin (AM), two modified compounds were identified: 1,6-dihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one (C1) and 1,6-dihydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one (C2). In addition, molecular dynamics simulations were conducted to analyze the interaction characteristics of the two bound BT-new compound complexes. During simulations, the TRP9, ARG50, VAL52, and GLN122 residues of BT-C1 that align to the identical residues in BT-AM generate consistent hydrogen bond interactions with 0-3 and 0-2. However, the BT-C2 complex has a different binding site, TYR 258, ILE 281, and SER 302, and can form more hydrogen bonds in the range 0-4. Therefore, this study reveals that C1 and C2 inhibit BT as an additive or synergistic effect; however, further in vitro and in vivo studies are needed.
doi_str_mv 10.3390/molecules27196338
format article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A745962581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A745962581</galeid><sourcerecordid>A745962581</sourcerecordid><originalsourceid>FETCH-LOGICAL-g671-aed7f9a6a71748737a13e83de8bd9549c4065e288d74a386ebd3c7e4d31ab0d63</originalsourceid><addsrcrecordid>eNptUMtOwzAQjBBIlMIHcLPEtWnt2ImTY1QerWgFEr1Xm3iTmiY2itNDPws-hG_CFA4VQnuY2dHMrLRBcM3omPOMTlrbYLlr0EWSZQnn6UkwYCKiIaciOz3i58GFc6-URkyweBC8z6yP2npPllZho0098uzQBR25teX2r7Q30OqSvOjW7722ZkTAKHLb7epwobdo0DliK9Jv8LtTVxoVyZu3DYRLMLV1vTYEatDG9QfT50e42hU7f5s8d7ZHjz4-z0sw_QZaiwWQR-z8rV67yfwyOKugcXj1i8NgdX-3ms7CxdPDfJovwjqRLARUssogAcmkSCWXwDimXGFaqCwWWSloEmOUpkoK4GmCheKlRKE4g4KqhA-Dm5_aGhpca1PZvoOy1a5c51LEWRLFKfOu8T8uPwr9k6zBSnv9KPAFjhWGEA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Homology Modeling, Molecular Docking, Molecular Dynamic Simulation, and Drug-Likeness of the Modified Alpha-Mangostin against the β-Tubulin Protein of IAcanthamoeba Keratitis/I</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Ongtanasup, Tassanee ; Mazumder, Anisha ; Dwivedi, Anupma ; Eawsakul, Komgrit</creator><creatorcontrib>Ongtanasup, Tassanee ; Mazumder, Anisha ; Dwivedi, Anupma ; Eawsakul, Komgrit</creatorcontrib><description>Acanthamoeba species are capable of causing amoebic keratitis (AK). As a monotherapy, alpha-mangostin is effective for the treatment of AK; however, its bioavailability is quite poor. Moreover, the efficacy of therapy is contingent on the parasite and virulent strains. To improve readiness against AK, it is necessary to find other derivatives with accurate target identification. Beta-tubulin (BT) has been used as a target for anti-Acanthamoeba (A. keratitis). In this work, therefore, a model of the BT protein of A. keratitis was constructed by homology modeling utilizing the amino acid sequence from NCBI (GenBank: JQ417907.1). Ramachandran Plot was responsible for validating the protein PDB. The verified BT PDB was used for docking with the specified ligand. Based on an improved docking score compared to alpha-mangostin (AM), two modified compounds were identified: 1,6-dihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one (C1) and 1,6-dihydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one (C2). In addition, molecular dynamics simulations were conducted to analyze the interaction characteristics of the two bound BT-new compound complexes. During simulations, the TRP9, ARG50, VAL52, and GLN122 residues of BT-C1 that align to the identical residues in BT-AM generate consistent hydrogen bond interactions with 0-3 and 0-2. However, the BT-C2 complex has a different binding site, TYR 258, ILE 281, and SER 302, and can form more hydrogen bonds in the range 0-4. Therefore, this study reveals that C1 and C2 inhibit BT as an additive or synergistic effect; however, further in vitro and in vivo studies are needed.</description><identifier>ISSN: 1420-3049</identifier><identifier>EISSN: 1420-3049</identifier><identifier>DOI: 10.3390/molecules27196338</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Analysis ; Drug therapy ; Hydrogen ; Keratitis ; Molecular dynamics ; Tubulins</subject><ispartof>Molecules (Basel, Switzerland), 2022-09, Vol.27 (19)</ispartof><rights>COPYRIGHT 2022 MDPI AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Ongtanasup, Tassanee</creatorcontrib><creatorcontrib>Mazumder, Anisha</creatorcontrib><creatorcontrib>Dwivedi, Anupma</creatorcontrib><creatorcontrib>Eawsakul, Komgrit</creatorcontrib><title>Homology Modeling, Molecular Docking, Molecular Dynamic Simulation, and Drug-Likeness of the Modified Alpha-Mangostin against the β-Tubulin Protein of IAcanthamoeba Keratitis/I</title><title>Molecules (Basel, Switzerland)</title><description>Acanthamoeba species are capable of causing amoebic keratitis (AK). As a monotherapy, alpha-mangostin is effective for the treatment of AK; however, its bioavailability is quite poor. Moreover, the efficacy of therapy is contingent on the parasite and virulent strains. To improve readiness against AK, it is necessary to find other derivatives with accurate target identification. Beta-tubulin (BT) has been used as a target for anti-Acanthamoeba (A. keratitis). In this work, therefore, a model of the BT protein of A. keratitis was constructed by homology modeling utilizing the amino acid sequence from NCBI (GenBank: JQ417907.1). Ramachandran Plot was responsible for validating the protein PDB. The verified BT PDB was used for docking with the specified ligand. Based on an improved docking score compared to alpha-mangostin (AM), two modified compounds were identified: 1,6-dihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one (C1) and 1,6-dihydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one (C2). In addition, molecular dynamics simulations were conducted to analyze the interaction characteristics of the two bound BT-new compound complexes. During simulations, the TRP9, ARG50, VAL52, and GLN122 residues of BT-C1 that align to the identical residues in BT-AM generate consistent hydrogen bond interactions with 0-3 and 0-2. However, the BT-C2 complex has a different binding site, TYR 258, ILE 281, and SER 302, and can form more hydrogen bonds in the range 0-4. Therefore, this study reveals that C1 and C2 inhibit BT as an additive or synergistic effect; however, further in vitro and in vivo studies are needed.</description><subject>Analysis</subject><subject>Drug therapy</subject><subject>Hydrogen</subject><subject>Keratitis</subject><subject>Molecular dynamics</subject><subject>Tubulins</subject><issn>1420-3049</issn><issn>1420-3049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptUMtOwzAQjBBIlMIHcLPEtWnt2ImTY1QerWgFEr1Xm3iTmiY2itNDPws-hG_CFA4VQnuY2dHMrLRBcM3omPOMTlrbYLlr0EWSZQnn6UkwYCKiIaciOz3i58GFc6-URkyweBC8z6yP2npPllZho0098uzQBR25teX2r7Q30OqSvOjW7722ZkTAKHLb7epwobdo0DliK9Jv8LtTVxoVyZu3DYRLMLV1vTYEatDG9QfT50e42hU7f5s8d7ZHjz4-z0sw_QZaiwWQR-z8rV67yfwyOKugcXj1i8NgdX-3ms7CxdPDfJovwjqRLARUssogAcmkSCWXwDimXGFaqCwWWSloEmOUpkoK4GmCheKlRKE4g4KqhA-Dm5_aGhpca1PZvoOy1a5c51LEWRLFKfOu8T8uPwr9k6zBSnv9KPAFjhWGEA</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Ongtanasup, Tassanee</creator><creator>Mazumder, Anisha</creator><creator>Dwivedi, Anupma</creator><creator>Eawsakul, Komgrit</creator><general>MDPI AG</general><scope/></search><sort><creationdate>20220901</creationdate><title>Homology Modeling, Molecular Docking, Molecular Dynamic Simulation, and Drug-Likeness of the Modified Alpha-Mangostin against the β-Tubulin Protein of IAcanthamoeba Keratitis/I</title><author>Ongtanasup, Tassanee ; Mazumder, Anisha ; Dwivedi, Anupma ; Eawsakul, Komgrit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g671-aed7f9a6a71748737a13e83de8bd9549c4065e288d74a386ebd3c7e4d31ab0d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Drug therapy</topic><topic>Hydrogen</topic><topic>Keratitis</topic><topic>Molecular dynamics</topic><topic>Tubulins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ongtanasup, Tassanee</creatorcontrib><creatorcontrib>Mazumder, Anisha</creatorcontrib><creatorcontrib>Dwivedi, Anupma</creatorcontrib><creatorcontrib>Eawsakul, Komgrit</creatorcontrib><jtitle>Molecules (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ongtanasup, Tassanee</au><au>Mazumder, Anisha</au><au>Dwivedi, Anupma</au><au>Eawsakul, Komgrit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Homology Modeling, Molecular Docking, Molecular Dynamic Simulation, and Drug-Likeness of the Modified Alpha-Mangostin against the β-Tubulin Protein of IAcanthamoeba Keratitis/I</atitle><jtitle>Molecules (Basel, Switzerland)</jtitle><date>2022-09-01</date><risdate>2022</risdate><volume>27</volume><issue>19</issue><issn>1420-3049</issn><eissn>1420-3049</eissn><abstract>Acanthamoeba species are capable of causing amoebic keratitis (AK). As a monotherapy, alpha-mangostin is effective for the treatment of AK; however, its bioavailability is quite poor. Moreover, the efficacy of therapy is contingent on the parasite and virulent strains. To improve readiness against AK, it is necessary to find other derivatives with accurate target identification. Beta-tubulin (BT) has been used as a target for anti-Acanthamoeba (A. keratitis). In this work, therefore, a model of the BT protein of A. keratitis was constructed by homology modeling utilizing the amino acid sequence from NCBI (GenBank: JQ417907.1). Ramachandran Plot was responsible for validating the protein PDB. The verified BT PDB was used for docking with the specified ligand. Based on an improved docking score compared to alpha-mangostin (AM), two modified compounds were identified: 1,6-dihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one (C1) and 1,6-dihydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one (C2). In addition, molecular dynamics simulations were conducted to analyze the interaction characteristics of the two bound BT-new compound complexes. During simulations, the TRP9, ARG50, VAL52, and GLN122 residues of BT-C1 that align to the identical residues in BT-AM generate consistent hydrogen bond interactions with 0-3 and 0-2. However, the BT-C2 complex has a different binding site, TYR 258, ILE 281, and SER 302, and can form more hydrogen bonds in the range 0-4. Therefore, this study reveals that C1 and C2 inhibit BT as an additive or synergistic effect; however, further in vitro and in vivo studies are needed.</abstract><pub>MDPI AG</pub><doi>10.3390/molecules27196338</doi></addata></record>
fulltext fulltext
identifier ISSN: 1420-3049
ispartof Molecules (Basel, Switzerland), 2022-09, Vol.27 (19)
issn 1420-3049
1420-3049
language eng
recordid cdi_gale_infotracmisc_A745962581
source Publicly Available Content Database; PubMed Central
subjects Analysis
Drug therapy
Hydrogen
Keratitis
Molecular dynamics
Tubulins
title Homology Modeling, Molecular Docking, Molecular Dynamic Simulation, and Drug-Likeness of the Modified Alpha-Mangostin against the β-Tubulin Protein of IAcanthamoeba Keratitis/I
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T05%3A30%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Homology%20Modeling,%20Molecular%20Docking,%20Molecular%20Dynamic%20Simulation,%20and%20Drug-Likeness%20of%20the%20Modified%20Alpha-Mangostin%20against%20the%20%CE%B2-Tubulin%20Protein%20of%20IAcanthamoeba%20Keratitis/I&rft.jtitle=Molecules%20(Basel,%20Switzerland)&rft.au=Ongtanasup,%20Tassanee&rft.date=2022-09-01&rft.volume=27&rft.issue=19&rft.issn=1420-3049&rft.eissn=1420-3049&rft_id=info:doi/10.3390/molecules27196338&rft_dat=%3Cgale%3EA745962581%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g671-aed7f9a6a71748737a13e83de8bd9549c4065e288d74a386ebd3c7e4d31ab0d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A745962581&rfr_iscdi=true